3
Announcements
Trials
Browse
Landscape
Status
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Gastrointestinal
4
Thoracic
1
Sarcoma
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Dermatologic
1
Conditions
Sarcoma
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Melanoma
2
Carcinoma, Renal Cell
2
Breast Neoplasms
2
Vulvar Neoplasms
1
Vaginal Neoplasms
1
Uterine Cervical Neoplasms
1
Urinary Bladder Neoplasms
1
Urethral Neoplasms
1
Thyroid Neoplasms
1
Testicular Neoplasms
1
Small Cell Lung Carcinoma
1
Salivary Gland Neoplasms
1
Mouth Neoplasms
1
Liver Neoplasms
1
Head and Neck Neoplasms
1
Glioma
1
Gastrointestinal Stromal Tumors
1
Gastrointestinal Neoplasms
1
Gallbladder Neoplasms
1
Fallopian Tube Neoplasms
1
Esophageal Neoplasms
1
Endometrial Neoplasms
1
Diabetes Mellitus, Insulin-Dependent, 12
1
Colorectal Neoplasms
1
Carcinoma, Transitional Cell
1
Interventions
pembrolizumab
21
Nivolumab
7
Docetaxel
7
Paclitaxel
5
Magnetic Resonance Spectroscopy
5
Carboplatin
5
Trastuzumab
4
Specimen Handling
4
Psychiatric Rehabilitation
4
Cyclophosphamide
4
tisotumab vedotin
3
fludarabine
3
atezolizumab
3
Taxes
3
Polymerase Chain Reaction
3
Gene Expression Profiling
3
Gemcitabine
3
Fluorouracil
3
Counseling
3
Cisplatin
3
Albumin-Bound Paclitaxel
3
ulixertinib
2
poly ICLC
2
durvalumab
2
belinostat
2
X-Rays
2
Standard of Care
2
Radiotherapy
2
Radiation
2
Oxaliplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Esophageal Neoplasms
×
trastuzumab deruxtecan
×
Genitourinary
×
Clear all
NCT07124000
2026-06-01
DP-04
AstraZeneca
Recruiting
100 enrolled